Disease Domain | Count |
---|---|
Immune System Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Recombinant polypeptide | 2 |
Small molecule drug | 1 |
Monoclonal antibody | 1 |
Biosimilar | 1 |
Top 5 Target | Count |
---|---|
MC1R x MC3R | 1 |
Target |
Mechanism MC1R agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Dec 2022 |
Sponsor / Collaborator |
Start Date30 Nov 2022 |
Sponsor / Collaborator SynAct Pharma ApS [+1] |
Start Date26 Sep 2022 |
Sponsor / Collaborator SynAct Pharma ApS [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Resomelagon ( MC1R x MC3R ) | Rheumatoid Arthritis More | Phase 2 |
TXP-35 | Autoimmune Diseases More | Preclinical |
TXP-11 | Multiple Organ Failure More | Preclinical |
TXP-59 | Autoimmune Diseases More | Preclinical |